Cargando…

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases

Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Pooladgar, Parham, Sakhabakhsh, Mehdi, Taghva, Arsia, Soleiman-Meigooni, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Brieflands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024338/
https://www.ncbi.nlm.nih.gov/pubmed/36942075
http://dx.doi.org/10.5812/ijpr-128408
_version_ 1784909081417351168
author Pooladgar, Parham
Sakhabakhsh, Mehdi
Taghva, Arsia
Soleiman-Meigooni, Saeed
author_facet Pooladgar, Parham
Sakhabakhsh, Mehdi
Taghva, Arsia
Soleiman-Meigooni, Saeed
author_sort Pooladgar, Parham
collection PubMed
description Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, multiple sclerosis, Parkinson's disease, psychiatric and mood disorders, and even infectious diseases. Hence, this study reviewed the therapeutic potential of this drug in treating Alzheimer's and other diseases by reviewing the articles from databases including Web of Science, Scopus, PubMed, Cochrane, and Science Direct. It was shown that donepezil could affect the pathophysiology of these diseases via mechanisms such as increasing the concentration of acetylcholine, modulating local and systemic inflammatory processes, affecting acetylcholine receptors like nicotinic and muscarinic receptors, and activating various cellular signaling via receptors like sigma-1 receptors. Despite many therapeutic potentials, this drug has not yet been approved for treating non-Alzheimer's diseases, and more comprehensive studies are needed.
format Online
Article
Text
id pubmed-10024338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Brieflands
record_format MEDLINE/PubMed
spelling pubmed-100243382023-03-19 Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases Pooladgar, Parham Sakhabakhsh, Mehdi Taghva, Arsia Soleiman-Meigooni, Saeed Iran J Pharm Res Review Article Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, multiple sclerosis, Parkinson's disease, psychiatric and mood disorders, and even infectious diseases. Hence, this study reviewed the therapeutic potential of this drug in treating Alzheimer's and other diseases by reviewing the articles from databases including Web of Science, Scopus, PubMed, Cochrane, and Science Direct. It was shown that donepezil could affect the pathophysiology of these diseases via mechanisms such as increasing the concentration of acetylcholine, modulating local and systemic inflammatory processes, affecting acetylcholine receptors like nicotinic and muscarinic receptors, and activating various cellular signaling via receptors like sigma-1 receptors. Despite many therapeutic potentials, this drug has not yet been approved for treating non-Alzheimer's diseases, and more comprehensive studies are needed. Brieflands 2022-08-16 /pmc/articles/PMC10024338/ /pubmed/36942075 http://dx.doi.org/10.5812/ijpr-128408 Text en Copyright © 2022, Author(s) https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Review Article
Pooladgar, Parham
Sakhabakhsh, Mehdi
Taghva, Arsia
Soleiman-Meigooni, Saeed
Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
title Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
title_full Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
title_fullStr Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
title_full_unstemmed Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
title_short Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
title_sort donepezil beyond alzheimer's disease? a narrative review of therapeutic potentials of donepezil in different diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024338/
https://www.ncbi.nlm.nih.gov/pubmed/36942075
http://dx.doi.org/10.5812/ijpr-128408
work_keys_str_mv AT pooladgarparham donepezilbeyondalzheimersdiseaseanarrativereviewoftherapeuticpotentialsofdonepezilindifferentdiseases
AT sakhabakhshmehdi donepezilbeyondalzheimersdiseaseanarrativereviewoftherapeuticpotentialsofdonepezilindifferentdiseases
AT taghvaarsia donepezilbeyondalzheimersdiseaseanarrativereviewoftherapeuticpotentialsofdonepezilindifferentdiseases
AT soleimanmeigoonisaeed donepezilbeyondalzheimersdiseaseanarrativereviewoftherapeuticpotentialsofdonepezilindifferentdiseases